Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13602183 | 0.92 | BRAF (0.51) | AURKAKDRAURKBHPGDBRD4 | |
| SCHEMBL13602232 | 0.89 | BRAF (0.42) | AURKAKDRAURKBHPGDBRAF | |
| SCHEMBL13689971 | 0.88 | AURKA (0.47) | AURKAKDRAURKBHPGDLMNA | |
| SCHEMBL13602187 | 0.87 | HPGD (0.53) | AURKAKDRAURKBHPGDLMNA | |
| SCHEMBL13689738 | 0.80 | AURKB (0.45) | AURKAKDRAURKBHPGDBRD4 | |
| SCHEMBL13602227 | 0.78 | MMP12 (0.41) | HPGD | |
| SCHEMBL8277193 | 0.78 | ALDH1A1 (0.53) | HPGDKDM4EALDH1A1 | |
| SCHEMBL13689975 | 0.77 | BRAF (0.37) | AURKAKDRAURKBHPGDBRD4 | |
| SCHEMBL13602268 | 0.77 | HPGD (0.63) | HPGDLMNABRD4ALDH1A1HSD17B10 | |
| SCHEMBL1018172 | 0.76 | ACLY (0.56) | AURKAKDRAURKBHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325962-A1 | TYROSINE DERIVATIVE | GENENTECH, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325962-A1 | TYROSINE DERIVATIVE | GENENTECH, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325962-A1 | TYROSINE DERIVATIVE | VCAM1, ICAM1, ITGB4 | AURKA 2003/4885KDR 22/4885AURKB 1928/4885 |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | CD22, ITGAM, FCGR3B | AURKA 3801/4885KDR 661/4885AURKB 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.